Clinical Trials

As a follow-up to our previous article portending the next new drug for Alzheimer’s, the FDA has now given approval under its accelerated approval pathway to the new medication Leqembi (originally known as Lecanemab). This drug was developed to help slow down cognitive decline in those with Mild Cognitive Impairment…

You may remember that more than a year ago, we posted a story on the arrival of a new drug approved by the FDA for the treatment of Alzheimer’s disease. That drug is Aduhelm, and while it is technically on the market and available, its use has been greatly limited…

It’s been almost 2 decades since the FDA approved any new therapeutics for the treatment of Alzheimer’s Disease. In that time, patients and families – as well as their care providers- have struggled with the reality of limited benefit from current medication options and a failure rate of 98.5% of…

While there may be no desire to return to our 20s or 30s, many of us wouldn’t mind if we could just slow down the aging process a bit: maybe forestall some of the aches and pains that seem to arise anew every few months, or lessen the challenges of…

We’re more than 6 months into the Coronavirus pandemic and our understanding of the virus, it’s impact, and strategies to keep ourselves safe continue to evolve. And now, added to this mix are a range of articles and alarms about vaccine development and second waves. It’s no wonder, then, that…

Receiving a diagnosis of Alzheimer’s is often the end result of a long and difficult process begun when memory or cognition begins to deteriorate and when other types of dementia are ruled out. What’s more, by the time a diagnosis is made there are likely few effective therapeutic options for…